Akero Therapeutics (AKRO) stock surged as much as 7.89% in premarket trading on Tuesday, fueled by promising late-stage trial data for its investigational drug efruxifermin and analyst optimism over the drug's potential commercial success.
The company announced positive 96-week results from the Phase 2b SYMMETRY trial, evaluating efruxifermin for the treatment of non-alcoholic steatohepatitis (NASH) with compensated cirrhosis. The data showed that 39% of patients treated with the 50mg dose of efruxifermin demonstrated reversal of cirrhosis without worsening of NASH, compared to only 15% in the placebo group.
Following the promising trial readout, multiple analysts raised their price targets and reiterated Buy or Overweight ratings on Akero shares, highlighting efruxifermin's potential to capture a significant share of the NASH market if approved. Notably, Morgan Stanley increased its price target to $96 from $46, citing expectations of commercial success for the drug.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。